Novel Strains and Their Uses

Abstract

The present invention relates to a strain selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP; and a cosmetic composition, a pharmaceutical external composition, or a food composition comprising any one or more selected from the group consisting of the above strains, cultures of the above strains, fermented products of the above strains, and fractions of the above cultures or fermented products. The Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides, or Bacillus megaterium strain, the culture of the above strain, the fermented product of the above strain, or the fraction of the culture or fermented product has an excellent effect of improving the skin and calming sensitive skin, and thus has a high utilization rate as a cosmetic composition, a pharmaceutical external composition, and a food composition for skin improvement. Therefore, various industrial applications such as cosmetics, pharmaceutical external products, and foods can be expected.

Description

Technical Field

[0001] The present invention relates to strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP; and cosmetic compositions, pharmaceutical external compositions, or food compositions comprising any one or more selected from the group consisting of the above strains, cultures of the above strains, fermented products of the above strains, and fractions of the above cultures or fermented products. Background Art

[0002] It is known that cosmetic ingredients generally cause various problems such as skin inflammation, acne, and swelling (Maibach.H.I., Contact Dermatitis, 6.369 - 404, 1980). In addition, various substances used as functional cosmetic raw materials also have problems of low skin stability or insignificant effects.

[0003] As an example, as cosmetics for improving skin wrinkles and elasticity, retinoids, adenosine, proteins derived from animal placentas, and chlorella extracts are known. The most well-known retinol has usage limitations due to safety issues such as irritation when applied to the skin, and it is actually difficult to expect effects of enhancing skin elasticity and improving wrinkles from chlorella extracts and the like due to their insignificant effects.

[0004] On the other hand, inflammation occurs when cells or tissues are damaged for some reason, and it presents for a series of defensive purposes to minimize the reaction and restore the damaged site to its original state, and it causes nerve and blood vessel, lymphatic vessel, body fluid reaction, and cell reaction, ultimately causing pain, swelling, redness, fever, etc., thus inducing dysfunction. Causes of inflammation include physical factors such as trauma, frostbite, burns, and radiation, chemical factors such as chemicals like acid, and immunological factors caused by antibody reactions. In addition, it is also caused by vascular or hormonal imbalances. Various chemical mediators secreted by cells damaged by external stimuli cause blood vessel dilation, and as permeability increases, antibodies, complements, plasma, and phagocytes rush to the inflamed site. This phenomenon causes erythema.

[0005] Those that play a role in eliminating the source of inflammation and reducing biological reactions and symptoms in order to eliminate inflammation are called anti-inflammatory agents. So far, as substances for anti-inflammatory purposes, there are non-steroidal flufenamic acid, ibuprofen, benzydamine, indomethacin, etc., and there are steroid-system prednisolone, dexamethasone, etc. However, most of them have problems in terms of skin safety or stability when contained in cosmetics, so their use is restricted.

[0006] Generally, a cosmetic composition for skin moisturization functions to make the human hair or skin look soft and lively by retaining a certain amount of moisture thereon, and has the function of preventing damages such as cracking and drying. That is, the cosmetic composition for skin moisturization is for the purpose of beautifying the skin or hair and maintaining its health by supplying or retaining a certain amount or more of moisture to the skin or hair.

[0007] Therefore, recently, a great deal of research has been conducted on cosmetic compositions that have excellent skin soothing, regenerating, moisturizing, antioxidant or anti-inflammatory effects and have excellent effects in improving skin conditions (such as wrinkles and elasticity) or preventing skin aging or skin damage. Summary of the Invention

[0008] Technical Problem

[0009] The present inventors have studied raw materials in natural resources that are safer and have excellent skin improvement effects, confirmed that the novel strain has skin improvement effects, and is significantly superior in skin improvement effects compared with existing yeast, Lactobacillus, and Bacillus fermentates, thereby completing the present invention.

[0010] Means for Solving the Problem

[0011] An object of the present invention is to provide a strain selected from the group consisting of Saccharomyces cerevisiae deposited under the accession number KCTC14779BP, Saccharomyces cerevisiae deposited under the accession number KCTC14780BP, Lactobacillus fructivorans deposited under the accession number KCTC14776BP, Bacillus paramycoides deposited under the accession number KCTC14777BP, and Bacillus megaterium deposited under the accession number KCTC14778BP.

[0012] Another object of the present invention is to provide a cosmetic composition for improving skin, which comprises any one or more of the above-mentioned strain, the culture of the above-mentioned strain, the fermented product of the above-mentioned strain, and the fraction of the above-mentioned culture or fermented product.

[0013] Another object of the present invention is to provide a pharmaceutical external preparation composition for improving skin, which comprises any one or more of the above-mentioned strain, the culture of the above-mentioned strain, the fermented product of the above-mentioned strain, and the fraction of the above-mentioned culture or fermented product.

[0014] Another object of the present invention is to provide a food composition for improving skin, which comprises any one or more of the above-mentioned strain, the culture of the above-mentioned strain, the fermented product of the above-mentioned strain, and the fraction of the above-mentioned culture or fermented product.

[0015] Another object of the present invention is to provide a method for preparing a fermented product, which comprises a step of fermenting by using a strain selected from the group consisting of Saccharomyces cerevisiae deposited under the accession number KCTC14779BP, Saccharomyces cerevisiae deposited under the accession number KCTC14780BP, Lactobacillus fructivorans deposited under the accession number KCTC14776BP, Bacillus paramycoides deposited under the accession number KCTC14777BP, and Bacillus megaterium deposited under the accession number KCTC14778BP.

[0016] Another object of the present invention is to provide a method for preparing a fraction, which comprises: a step of culturing a Saccharomyces cerevisiae strain deposited under the accession number KCTC14780BP; and a step of separating from the culture or fermented product of the strain by using water, an alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform or dichloromethane.

[0017] Advantages of the Invention

[0018] The Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides or Bacillus megaterium strain of the present invention, the culture of the above-mentioned strain, the fermented product of the above-mentioned strain, the fermented product of the above-mentioned strain or the fraction of the above-mentioned culture or fermented product have excellent skin improvement effects, and thus have a high utilization rate as a cosmetic composition, a pharmaceutical external preparation composition and a food composition for improving skin. Therefore, various industrial applications such as cosmetics, pharmaceutical external preparations, and foods can be expected. Detailed Embodiments

[0019] The following is a specific description of the content of the present invention. On the other hand, the descriptions and embodiments of one aspect disclosed in the present invention can also be applied to the descriptions and embodiments of other aspects for common matters. In addition, all combinations of various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, it is not considered that the scope of the present invention is limited by the specific descriptions described below.

[0020] One aspect of the present invention provides a strain selected from the group consisting of Saccharomyces cerevisiae deposited under the accession number KCTC14779BP, Saccharomyces cerevisiae deposited under the accession number KCTC14780BP, Lactobacillus fructivorans deposited under the accession number KCTC14776BP, Bacillus paramycoides deposited under the accession number KCTC14777BP, and Bacillus megaterium deposited under the accession number KCTC14778BP.

[0021] The term "Saccharomyces cerevisiae" in the present invention refers to a type of yeast belonging to the family Saccharomycetaceae and the genus Saccharomyces. This species has played an important role in winemaking, baking, and brewing since ancient times and has been widely used. For Saccharomyces cerevisiae, its characteristics may change according to the growth region and natural environmental conditions, and thus the strain and the activity of its fermentation products may change. The Saccharomyces cerevisiae of the present invention may be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Saccharomyces cerevisiae strain may be the strain deposited under KCTC14779BP or KCTC14780BP, but is not limited thereto.

[0022] The term "Lactobacillus fructivorans" in the present invention is a positive bacterium and refers to a type of lactic acid bacterium (lactobacillus) belonging to the genus Fructilactobacillus. This species has been found in wine, beer, must, dairy products, salted cabbage, meat, and fish. For Lactobacillus fructivorans, its characteristics may change according to the growth region and natural environmental conditions, and thus the strain and the activity of its fermentation products may change. The Lactobacillus fructivorans of the present invention may be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Lactobacillus fructivorans strain may be the strain deposited under KCTC14776BP, but is not limited thereto.

[0023] The term "Bacillus paramycoides" in the present invention belongs to Firmicutes and refers to the Bacillus species. For Bacillus paramycoides, its characteristics may change according to the growth region and natural environmental conditions, and thus the activities of the strain and its ferment may change. The Bacillus paramycoides of the present invention may be derived from the fermentation broth, but is not limited thereto. Specifically, in the present invention, the Bacillus paramycoides strain may be the strain deposited as KCTC14777BP, but is not limited thereto.

[0024] The term "Bacillus megaterium (Bacillus megaterium, hay bacillus, Priestia megaterium)" in the present invention is rod-shaped and Gram-positive, and is an aerobic spore-forming bacterium mainly found in various habitats. It refers to a kind of Bacillus belonging to the family Bacillus and the genus Priestia. It is widely used as a feed additive for poultry, livestock, aquatic animals, ruminants, etc. For Bacillus megaterium, its characteristics may change according to the growth region and natural environmental conditions, and thus the activities of the strain and its ferment may change. The Bacillus megaterium of the present invention may be derived from the fermentation broth, but is not limited thereto. Specifically, in the present invention, the Bacillus megaterium strain may be the strain deposited as KCTC14778BP, but is not limited thereto.

[0025] In the present invention, the fermentation broth can be prepared by fermenting for 6 months to 2 years, specifically 9 months to 1 year and 6 months, and more specifically 1 year. The above fermentation broth may be a plant fermentation broth, but is not limited thereto.

[0026] In a specific example of the present invention, a fermentation broth was prepared, and it was confirmed that compared with the fermentation products of common yeasts such as Saccharomyces cerevisiae, common lactic acid bacteria such as Lactobacillus fructivorans, common Bacillus such as Bacillus paramycoides or Bacillus megaterium, the fermentation products of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus paramycoides or Bacillus megaterium of the present invention have excellent skin-improving effects.

[0027] Another aspect of the present invention provides a cosmetic composition for skin improvement, which contains any one or more of the above-mentioned strains, the cultures of the above-mentioned strains, the fermentation products of the above-mentioned strains, and the fractions of the above-mentioned cultures or fermentation products.

[0028] In the terms of the present invention, the term "strain" refers to a collection of individuals derived from a single cell and having homogeneous genetic characteristics through asexual reproduction. There are multiple genetic variants within a species. In the present invention, the strain refers to Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus parafungiformis or Bacillus megaterium, specifically, it can be one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus parafungiformis KCTC14777BP and Bacillus megaterium KCTC14778BP, but not limited thereto.

[0029] In the present invention, the above-mentioned strain may include the cells of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus parafungiformis or Bacillus megaterium strains, dried cells, disrupted products, etc. At this time, the above-mentioned dried cells may be dried bacteria such as spray-dried bacteria, freeze-dried bacteria, vacuum-dried bacteria, drum-dried bacteria, etc., and the above-mentioned disrupted products may be products obtained by breaking the cell wall of the strain itself by chemical or physical force.

[0030] The "culture" of the present invention refers to a product obtained by culturing the above-mentioned strain in a medium. For example, the culture of the present invention may include the components remaining in the medium after harvesting the above-mentioned strain from a medium of one or more strains selected from the group consisting of Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus parafungiformis and Bacillus megaterium, or may include the components of the medium containing the strain.

[0031] The above-mentioned culture may be the whole culture, culture supernatant, disrupted product, fractions thereof, etc. of the above-mentioned Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus parafungiformis and / or Bacillus megaterium strains. At this time, the above-mentioned culture supernatant can be obtained by centrifuging the culture of the above-mentioned strain, the above-mentioned disrupted product can be obtained by physically or ultrasonically treating the above-mentioned strain, and the above-mentioned fractions can be obtained by applying the above-mentioned culture, culture supernatant, disrupted product, etc. to methods such as centrifugation, chromatography.

[0032] The medium and other culture conditions used in the culture of the strain of the present invention can be arbitrarily used without particular limitation as long as they are media used in the culture of conventional Saccharomyces, Lactobacillus and / or Bacillus microorganisms. Specifically, the strain of the present invention can be cultured in a conventional medium containing appropriate carbon sources, nitrogen sources, phosphorus sources, inorganic compounds, amino acids and / or vitamins, etc., under aerobic or anaerobic conditions while adjusting the temperature, pH, etc.

[0033] In the present invention, as the above carbon source, carbohydrates such as glucose, fructose, sucrose, maltose, etc. can be included; sugar alcohols such as mannitol, sorbitol, etc., organic acids such as pyruvic acid, lactic acid, citric acid, etc.; amino acids such as glutamic acid, methionine, lysine, etc., but not limited thereto. In addition, natural organic nutrient sources such as starch hydrolyzate, molasses, blackstrap molasses, rice bran, cassava, bagasse, and corn steep liquor can be used, and carbohydrates such as glucose and sterilized pre-treated molasses (i.e., molasses converted to reducing sugar) can be used, and other appropriate carbon sources can be used diversely without limitation. These carbon sources can be used alone or in combination of two or more.

[0034] As the above nitrogen source, inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, ammonium nitrate, etc. can be used; organic nitrogen sources such as amino acids, peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or its decomposition products, defatted soybean cake or its decomposition products, etc. These nitrogen sources can be used alone or in combination of two or more, but not limited thereto.

[0035] As the above phosphorus source, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, or corresponding sodium-containing salts, etc. can be included. As inorganic compounds, sodium chloride, calcium chloride, ferric chloride, magnesium sulfate, ferric sulfate, manganese sulfate, calcium carbonate, etc. can be used.

[0036] In addition, the above medium can include amino acids, vitamins, and / or appropriate precursors, etc. Specifically, L-amino acids, etc. can be added to the medium of the above strain. Specifically, glycine, glutamate, and / or cysteine, etc. can be added, and L-amino acids such as lysine can be further added as needed, but not necessarily limited thereto.

[0037] The above medium or precursor can be added to the culture in a batch or continuous manner, and not limited thereto.

[0038] In the present invention, during the cultivation of the strain, the pH of the culture can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. to the culture in an appropriate manner. In addition, during the cultivation process, the generation of bubbles can be inhibited by using an antifoaming agent such as fatty acid polyethylene glycol ester. In addition, oxygen or an oxygen-containing gas can be injected into the culture to maintain the aerobic state of the culture, or gas can not be injected or nitrogen, hydrogen, or carbon dioxide gas can be injected to maintain the anaerobic and microaerobic states.

[0039] The temperature of the culture can be from 25°C to 40°C, more specifically from 28°C to 37°C, but is not limited thereto. The culture time can continue until the desired amount of useful substance is produced, specifically from 1 hour to 200 hours, but is not limited thereto.

[0040] In the present invention, the term "fermentation" refers to the part that is not a putrefaction reaction during the process of microorganisms decomposing organic matter using the enzymes they possess. Fermentation reactions and putrefaction reactions proceed through similar processes, but in terms of the decomposition results, if useful substances are produced, it is called fermentation, and if malodorous or harmful substances are produced, it is called putrefaction.

[0041] In the present invention, the method for obtaining a fermented product from the above-mentioned strain is not particularly limited. It can be obtained by inoculating the strain into a culture medium, culturing it with shaking at 20°C to 40°C for 1 hour to 200 hours, separating the cells by centrifugation, and then disrupting the cells by ultrasonic treatment. Alternatively, it can be obtained according to methods commonly used in this technical field or similar fields.

[0042] In the present invention, for the culture medium inoculated with the strain, the type of the culture medium is not limited as long as the strain can ferment.

[0043] In the present invention, the fermented product obtained from the above-mentioned strain includes not only the fermented substance itself, but also all kinds of substances including the fermented product produced by the above-mentioned strain. For example, the culture medium of the strain in which the strain and the culture coexist, the fermented product obtained by filtering the strain from the above-mentioned culture medium, the fermented product obtained by sterilizing the strain in the above-mentioned culture medium and filtering it, the extract obtained by extracting the above-mentioned fermented product or the culture medium containing it, the dilution obtained by diluting the above-mentioned fermented product or its extract, the dried product obtained by drying the above-mentioned fermented product or its extract, the lysate obtained by collecting and disrupting the cells of the above-mentioned strain, etc.

[0044] The term "fraction" in the present invention refers to a product obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various components.

[0045] In the present invention, the fractionation method for obtaining the above-mentioned fraction is not particularly limited and can be carried out according to methods commonly used in this technical field. As non-limiting examples of the above-mentioned fractionation method, a method for obtaining a fraction from the above-mentioned extract by treating the extract obtained by culturing or fermenting the strain with a predetermined solvent can be cited.

[0046] In the present invention, the type of the solvent used to obtain the above fractions is not particularly limited, and any solvent known in the art can be used. As non-limiting examples of the above fractionation solvents, polar solvents such as water and alcohols can be mentioned; non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane can be mentioned. They can be used alone or in combination of two or more. When an alcohol in the above fractionation solvents is used, an alcohol having 1 to 4 carbon atoms can be preferably used.

[0047] In the present invention, the fraction may include a polypeptide extracted from a culture or fermentation product of a strain.

[0048] In the present invention, a peptide refers to a polymer in which amino acid monomers are artificially or spontaneously linked, a substance in which two or more amino acids are combined, and is called a tripeptide, oligopeptide, or polypeptide according to the number of amino acids. Specifically, in the present invention, a polypeptide may refer to a polypeptide containing 100 or more amino acids, but is not limited thereto.

[0049] In the present invention, "a polypeptide extracted from a culture or fermentation product of a strain" means obtaining a culture or fermentation product from a strain, and then separating an aggregate or polypeptide of a certain size or more having functionality in the culture or fermentation product. In the present invention, the terms "a polypeptide extracted from a culture or fermentation product of a strain", "yeast polypeptide", and "fraction" are used interchangeably.

[0050] In the present invention, the method for separating the fraction from the fermentation product is not particularly limited, but the fraction can be obtained by concentrating and precipitating (solvent, centrifugation process) only the supernatant from the lysate of the cells obtained by fermenting and disrupting the strain, and then spray drying.

[0051] The term "improving the skin" in the present invention may be any one or more selected from the group consisting of moisturizing the skin, improving wrinkles, improving elasticity, preventing aging, soothing the skin, regenerating the skin, improving skin inflammation, whitening the skin, antioxidant, anti-aging, protecting the skin from external stimuli, soothing sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, strengthening the skin barrier function, and alleviating skin irritation, but is not limited thereto.

[0052] As used in the present invention, the term "improvement" refers to all actions that at least reduce a parameter related to the alleviation or treatment of a condition, such as the degree of a symptom, and may include all of moisturizing the skin, improving wrinkles, improving elasticity, preventing aging, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, antioxidant, anti-aging, protecting the skin from external stimuli, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, strengthening the skin barrier function, alleviating skin irritation, and alleviating skin pain, among others.

[0053] The above-mentioned improvement of the skin can be achieved by promoting hyaluronic acid production, promoting collagen synthesis, enhancing cell activity, inhibiting NO production, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 (Prostaglandin E2) expression, increasing LOR (Loricrin) expression, inhibiting TNF-a expression, or inhibiting TRPV1 activity, but is not limited thereto.

[0054] Specifically, the present inventors confirmed that the fermented products of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptides, the fermented product of Lactobacillus fructivorans KCTC14776BP, the fermented product of Bacillus parafungiformis KCTC14777BP, and the fermented product of Bacillus megaterium KCTC14778BP have excellent skin improvement effects compared to the fermented products of ordinary yeast, ordinary lactobacilli, and ordinary bacilli. More specifically, it was confirmed that the fermented products of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptides, the fermented product of Lactobacillus fructivorans KCTC14776BP, the fermented product of Bacillus parafungiformis KCTC14777BP, or the fermented product of Bacillus megaterium KCTC14778BP have excellent effects of enhancing collagen synthesis, enhancing hyaluronic acid synthesis, enhancing cell activity, inhibiting NO production, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 expression, increasing LOR expression, inhibiting TNF-a expression, or inhibiting TRPV1 activity, etc.

[0055] Therefore, it was confirmed that the Saccharomyces cerevisiae, Lactobacillus fructivorans, Bacillus parafungiformis, Bacillus megaterium of the present invention, their fermented products, and / or fractions of the fermented products have excellent skin improvement effects such as improving wrinkles, improving elasticity, preventing aging, moisturizing the skin, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, antioxidant, anti-aging, protecting the skin from external stimuli, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, strengthening the skin barrier function, alleviating skin irritation, and alleviating skin pain, compared to ordinary yeast, ordinary lactobacilli, ordinary bacilli, or their fermented products.

[0056] In the terms of the present invention, "wrinkles" can be generally classified into expression wrinkles caused by facial expression muscles for making facial expressions and fine lines caused by overall or local skin aging. Specifically, wrinkles can be induced by reasons caused by genes, reduction of collagen and elastic fibers existing in the dermis of the skin, external environment, etc. For the purpose of the present invention, wrinkles can be used in the meaning including all expression wrinkles or fine lines, and are not limited thereto.

[0057] In the terms of the present invention, "elasticity" refers to the force that keeps the skin tight when pressed with fingers, and "improving elasticity" or "enhancing elasticity" refers to improving the elasticity of the skin by strengthening the structure of the subcutaneous fat layer of an individual, and can refer to improving the elasticity of the skin by using the composition of the present invention.

[0058] In the terms of the present invention, "aging" refers to the phenomenon that the structure and function of an organism decline over time. The prevention of aging in the present invention is not limited to its degree, etc., as long as aging is improved (for example, preventing, inhibiting, delaying aging, etc.). In the present invention, improving wrinkles and preventing aging may be due to promoting collagen synthesis, but are not limited thereto.

[0059] In the terms of the present invention, "Collagen" is a fibrin that is mostly found in most animals, especially mammals, and accounts for most of all connective tissues in the body such as skin and cartilage. The most common cells in the body, fibroblasts, generate and secrete collagen. Gelatin, which is widely used in cooking, or the food and pharmaceutical industries, is obtained by irreversible hydrolysis of collagen. The reduction of collagen is the main reason for inducing wrinkles and reducing skin elasticity. Therefore, the synthesis of collagen is crucial for improving wrinkles and enhancing elasticity.

[0060] In a specific example of the present invention, it was confirmed that the collagen synthesis enhancement rates of the yeasts of the present invention, namely Saccharomyces cerevisiae KCTC14779BP fermentate, Saccharomyces cerevisiae KCTC14780BP fermentate and / or yeast polypeptide, Lactobacillus fructivorans KCTC14776BP fermentate or Bacillus paramycoides KCTC14777BP fermentate, are excellent, and thus it was confirmed that the yeast fermentates, yeast polypeptides, Lactobacillus fermentates or Bacillus fermentates of the present invention have significant effects on improving skin wrinkles, enhancing elasticity, etc. (Tables 3, 4, 5, 6).

[0061] In the terms of the present invention, "moisturizing the skin" refers to all actions of maintaining the softness of the skin by supplying moisture to the skin or blocking the evaporation of moisture and maintaining a smooth surface by inducing uniform exfoliation of cutin, and "dryness" refers to a state in which such skin moisturization is insufficient. The skin moisturizing effect can help improve skin wrinkles and increase elasticity. Specifically, moisturizing the skin may be due to promoting the production of hyaluronic acid, but is not limited thereto.

[0062] In the terms of the present invention, "hyaluronic acid" is a kind of glycosaminoglycans and refers to a chain-like high-molecular polysaccharide substance in which glucuronic acid and N-acetylglucosamine residues are repeatedly linked. Hyaluronic acid can contain 300 to 1000 times its own weight of water, so it binds to moisture and exhibits a moisturizing effect on the skin.

[0063] In a specific example of the present invention, it was confirmed that the fermentation products of the yeast of the present invention, namely Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP fermentation product or Bacillus megaterium KCTC14778BP fermentation product, have excellent hyaluronic acid synthesis enhancement rates, and thus it was confirmed that the yeast fermentation products, yeast polypeptides or Bacillus fermentation products of the present invention have significant effects on anti-aging, skin moisturization, etc. (Tables 7, 8, 9, 10, 11).

[0064] In the terms of the present invention, "regeneration" refers to inhibiting the decline in the function of cells, tissues or organs or restoring the declined function. The decline in the function of cells, tissues or organs may be due to damage to cells, tissues, organs. Such damage may be caused by various factors such as radiotherapy, drug treatment, surgery, infection, inflammation, degenerative diseases, autoimmune diseases, aging, etc. On the other hand, the above-mentioned regeneration can be achieved by promoting cell differentiation, but is not limited thereto. "Regenerating the skin" in the present invention refers to repairing the damaged part of the skin tissue again. In the present invention, regenerating the skin may be due to enhanced cell activity, but is not limited thereto.

[0065] In a specific example of the present invention, it was confirmed that there is no effect on cell activity in ordinary yeast fermentation products, while the cell activity rate is significantly high in the fermentation product and / or yeast polypeptide of the yeast of the present invention, namely Saccharomyces cerevisiae KCTC14780BP (Table 12).

[0066] In the terms of the present invention, "calming the skin" refers to relieving and calming erythema, itching, irritated skin or sensitive parts, etc., and may be a concept including relieving skin irritation. For example, relieving skin pruritus, relieving skin pain, reducing water loss of the skin and / or reducing telangiectasia can be cited, but is not limited thereto.

[0067] In the terms of the present invention, "inflammation" is a biological reaction in an organism to damage or infection of a specific tissue, and the main mediators are immune cells. The purpose of this inflammation is to maximize the inhibition of tissue damage, remove the infective agent, and regenerate the tissue. In the present invention, sedation and regeneration of the skin may be due to the inhibition of NO production, but are not limited thereto.

[0068] The term "NO (nitric oxide)" in the present invention has various functions such as removing bacteria and tumors, regulating blood pressure, or mediating neurotransmission. However, if an inflammatory reaction occurs, the expression of iNOS (inducible nitric oxide synthase) in related cells will increase, generating a large amount of NO. The over-produced NO will induce tissue damage, gene mutation, nerve damage, etc., and increase vascular permeability, promoting inflammatory reactions such as edema. The production of NO increases in the cells that induce inflammation, and if the skin is sedated, the production of NO is inhibited, so there is a necessary correlation between them.

[0069] In a specific example of the present invention, it was confirmed that the ability of the ferment of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptide or the ferment of Lactobacillus, Lactobacillus fructivorans KCTC14776BP, to inhibit NO production is also superior to that of ordinary yeast or Lactobacillus ferment, and thus it was confirmed that the ferment of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptide or the ferment of Lactobacillus, Lactobacillus fructivorans KCTC14776BP, has the effects of sedating the skin and improving inflammation (Tables 13 and 14).

[0070] In the present invention, the term "whitening" refers to methods including increasing the brightness of the skin whose brightness has decreased due to excessive pigments such as melanin or maintaining the brightness of the skin at a certain level, the skin with increased brightness formed by the above methods, etc. Specifically, it may refer to whitening the skin. The above "whitening the skin" can be understood as that as the activity of tyrosinase is inhibited, the production of melanin is inhibited, thereby improving the symptoms caused by the increase of melanin, such as dark spots and freckles.

[0071] In a specific example of the present invention, when the ferment of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptide are treated, the inhibition rate of melanin production is excellent, thus confirming the skin whitening effect (Table 15).

[0072] In the present invention, the term "antioxidant" refers to all actions including inhibiting oxidation. Specifically, it may refer to the action of removing free radicals such as reactive oxygen species, but is not limited thereto. Reactive oxygen species oxidize and damage cells in the body, thus exposing to various diseases. In addition, a complex antioxidant defense network is also formed on the skin, which counteracts reactive oxygen species and thus has a protective effect. Therefore, antioxidant may be related to the effect of "protecting the skin from external stimuli".

[0073] The term "anti-aging" in the present invention refers to inhibiting or alleviating the progress of aging. The aging of cells refers to the oxidation of cells, and appropriately maintaining reactive oxygen species can be regarded as the main principle for preventing cell oxidation and cell aging.

[0074] In a specific example of the present invention, when treating the fermented product of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptide, the effect of scavenging free radicals (reactive oxygen species) is excellent, thereby confirming the effects of antioxidant, anti-aging, and protecting the skin from external stimuli (Table 16).

[0075] The term "sensitive skin" in the present invention refers to skin that is more sensitive to external irritants, allergens, or environmental changes or internal causes of the human body than normal skin, and thus is prone to cause irritation reactions or dermatitis. It refers to various skin reactions such as erythema (redness), cutin, blisters, etc. and subjective symptoms such as itching, stinging, irritation, pain, burning, etc. due to external stimuli such as cosmetics and internal causes such as hormonal changes.

[0076] In a specific example of the present invention, when treating the fermented product of the yeast of the present invention, Saccharomyces cerevisiae KCTC14780BP, and / or yeast polypeptide, the effects of inhibiting the expression of erythema / itching inducer (PGE2), increasing the expression of the main component of the skin barrier, LOR (Loricrin), inhibiting the expression of inflammatory cytokine (TNF-a), and inhibiting the activity of skin nerve irritation inducer (TRPV1) are excellent, thereby confirming the effects of sedating and / or improving sensitive skin by alleviating the representative phenomena of erythema / itching, irritation / pain in sensitive skin and strengthening the skin barrier (Tables 17, 18, 19, 20).

[0077] The term "cosmetic composition" of the present invention may be a dosage form selected from the group consisting of solutions, external ointments, creams, foams, nutritious lotions, softeners, perfumes, facial masks, soft waters, emulsions, makeup primers, essences, soaps, liquid cleaners, bath salts, sunscreen creams, sunscreen oils, suspensions, emulsions, pastes, gels, lotions, powders, soaps, cleaning agents containing surfactants, oils, powder foundations, emulsion foundations, wax foundations, patches, and sprays, but is not limited thereto.

[0078] The cosmetic composition of the present invention may additionally contain one or more cosmetically acceptable carriers incorporated in ordinary skin cosmetics. As conventional components, for example, oil components, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately incorporated, but are not limited thereto.

[0079] The cosmetically acceptable carriers contained in the cosmetic composition of the present invention vary depending on the dosage form of the above cosmetic composition.

[0080] When the dosage form of the present invention is an ointment, paste, cream or gel, as carrier components, animal oils, vegetable oils, waxes, paraffin waxes, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc, zinc oxide, etc. can be used, but are not limited thereto. These can be used alone or in combination of two or more.

[0081] When the dosage form of the present invention is a solution or emulsion, as carrier components, solvents, solubilizers or emulsifying agents, etc. can be used. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, etc. can be used. In particular, cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerol fatty acid esters, polyethylene glycol or fatty acid esters of sorbitan anhydride can be used, but are not limited thereto. These can be used alone or in combination of two or more.

[0082] When the dosage form of the present invention is a suspension, as carrier components, liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan esters and polyoxyethylene sorbitan anhydride esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used, but are not limited thereto. These can be used alone or in combination of two or more.

[0083] When the dosage form of the present invention is a soap, as carrier components, alkali metal salts of fatty acids, fatty acid semi-esters salts, fatty acid protein hydrolysates, hydroxyethyl sulfonates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. can be used, but are not limited thereto. These can be used alone or in combination of two or more.

[0084] When the dosage form of the present invention is a powder or spray, as carrier components, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof can be used. In particular, when it is a spray, a propellant such as chlorofluorocarbon, propane / butane or dimethyl ether can be additionally contained.

[0085] As a specific embodiment of the present invention, a cosmetic composition containing Saccharomyces cerevisiae KCTC14779BP for improving wrinkles, for improving elasticity, for preventing aging or for moisturizing the skin can be provided, but is not limited thereto.

[0086] As a specific embodiment of the present invention, there may be provided a cosmetic composition comprising Saccharomyces cerevisiae KCTC14780BP for calming the skin, for skin regeneration, for improving skin inflammation, for moisturizing the skin, for improving wrinkles, for improving elasticity, for whitening the skin, for antioxidant, for anti-aging, for calming sensitive skin, for improving sensitive skin, for relieving erythema, for relieving pruritus or for strengthening the skin barrier function, but not limited thereto.

[0087] As a specific embodiment of the present invention, there may be provided a cosmetic composition comprising Lactobacillus fructivorans KCTC14776BP for improving wrinkles, for improving elasticity, for preventing aging, for calming the skin, for improving skin inflammation or for moisturizing the skin, but not limited thereto.

[0088] As a specific embodiment of the present invention, there may be provided a cosmetic composition comprising Bacillus parafungiformis KCTC14777BP for improving wrinkles, for improving elasticity, for preventing aging or for moisturizing the skin, but not limited thereto.

[0089] As a specific embodiment of the present invention, there may be provided a cosmetic composition comprising Bacillus megaterium KCTC14778BP for moisturizing the skin, but not limited thereto.

[0090] On the other hand, all the components described in the present invention can preferably be included in the composition of the present invention within the range not exceeding the maximum use values specified in relevant regulations such as cosmetic safety standards and the "Cosmetic Safety and Technical Specifications" in China.

[0091] Another aspect of the present invention provides a pharmaceutical external composition for skin improvement, which comprises any one or more of the above-mentioned strains, cultures of the above-mentioned strains, fermentates of the above-mentioned strains, and fractions of the above-mentioned cultures or fermentates.

[0092] The above-mentioned "Saccharomyces cerevisiae", "Lactobacillus fructivorans", "Bacillus parafungiformis", "Bacillus megaterium", "strains", "cultures", "fermentates", "fractions", "yeast polypeptides", "improving skin", "improving", "wrinkles", "elasticity", "collagen", "aging", "moisturizing skin", "hyaluronic acid", "regeneration", "calming skin", "inflammation" and "NO", "whitening", "antioxidant", "protecting skin from external stimuli", "anti-aging" and "sensitive skin" are as described above.

[0093] The term "quasi-drug" of the present invention may be selected from the group consisting of, but not limited to, body wash, disinfectant cleaner, cleaner, kitchen cleaner, cleaning cleaner, toothpaste, mouthwash, wet tissue, lotion, soap, hand sanitizer, hair cleaner, hair softener, humidifier filler, facial mask, ointment, and filter filler.

[0094] In addition to the above components, the quasi-drug composition of the present invention may further contain a pharmaceutically acceptable carrier, excipient, or diluent as needed. There is no limitation on the above pharmaceutically acceptable carrier, excipient, or diluent as long as it does not impair the effects of the present invention. For example, it may include fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, and the like.

[0095] Representative examples of the pharmaceutically acceptable carrier, excipient, or diluent of the present invention may include lactose, glucose (dextrose), sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerol, gum arabic, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl paraben, propyl paraben, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, witepsol, macrogol, Tween 61, cocoa butter, Laurinum, and the like.

[0096] When the culture of the strain of the present invention, its fermented product, or a fraction of the above culture or fermented product is used as a quasi-drug, it may additionally contain one or more active ingredients exhibiting the same or similar functions. For example, it may contain known ingredients for enhancing skin beneficial bacteria, inhibiting skin harmful bacteria, soothing the skin, improving skin inflammation, whitening the skin, regenerating the skin, and healing wounds. If additional ingredients for improving wrinkles, whitening the skin, improving skin problems, and moisturizing the skin are included, the effects of the composition of the present invention in improving wrinkles, improving elasticity, moisturizing the skin, preventing aging, soothing the skin, regenerating the skin, and improving skin inflammation can be further enhanced. When adding the above ingredients, the skin safety, ease of formulation, and stability of the active ingredients resulting from combined use may be considered.

[0097] The pharmaceutical external preparation composition of the present invention may additionally contain one or more components selected from the group consisting of retinoic acid, TGF, proteins derived from animal placenta, betulinic acid, and chlorella extract, which are known in the art as anti-skin aging or moisturizing components; non-steroidal flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azulene, and hydrocortisone, which are known in the art as anti-inflammatory components; and their derivatives and various plant extracts. The content of the additional component may be from 0.0001% by weight to 10% by weight relative to the total weight of the composition, and the above content range may be adjusted according to conditions such as skin safety, the strain of the present invention, the culture of the strain, the fermented product, or the ease of formulation of the fraction extracted from the fermented product of the above strain.

[0098] The methods of formulating pharmaceutical external preparations, dosages, usage methods, constituent components, etc. can be appropriately selected from conventional techniques known in the technical field.

[0099] As a specific embodiment of the present invention, there may be provided a pharmaceutical external preparation composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin, which contains Saccharomyces cerevisiae KCTC14779BP, but is not limited thereto.

[0100] As a specific embodiment of the present invention, there may be provided a pharmaceutical external preparation composition for calming the skin, regenerating the skin, improving skin inflammation, moisturizing the skin, improving wrinkles, improving elasticity, whitening the skin, antioxidizing, anti-aging, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, or strengthening the skin barrier function, which contains Lactobacillus fructivorans KCTC14776BP, but is not limited thereto.

[0101] As a specific embodiment of the present invention, there may be provided a pharmaceutical external preparation composition for improving wrinkles, improving elasticity, preventing aging, calming the skin, improving skin inflammation, or moisturizing the skin, which contains Lactobacillus fructivorans KCTC14776BP, but is not limited thereto.

[0102] As a specific embodiment of the present invention, there may be provided a pharmaceutical external preparation composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin, which contains Bacillus paramycoides KCTC14777BP, but is not limited thereto.

[0103] As a specific embodiment of the present invention, there may be provided a pharmaceutical external preparation composition for moisturizing the skin, which contains Bacillus megaterium KCTC14778BP, but is not limited thereto.

[0104] Another aspect of the present invention provides a food composition for improving skin, which comprises any one or more of the above-mentioned strains, cultures of the above-mentioned strains, fermented products of the above-mentioned strains, and fractions of the above-mentioned cultures or fermented products.

[0105] The above-mentioned "Saccharomyces cerevisiae", "Lactobacillus fructivorans", "Bacillus parafungiformis", "Bacillus megaterium", "strain", "culture", "fermented product", "fraction", "yeast polypeptide", "improve skin", "improve", "wrinkle", "elasticity", "collagen", "aging", "moisturize skin", "hyaluronic acid", "regeneration", "soothe skin", "inflammation", "NO", "whitening", "antioxidation", "protect skin from external stimuli", "anti-aging" and "sensitive skin" are as described above.

[0106] The term "food" of the invention includes all foods in the general sense, such as meat, sausage, bread, chocolate, confectionery, snacks, cookies, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, oral liquids, alcoholic beverages, vitamin complexes, health functional foods, etc., and is not limited thereto, as long as it can include one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus parafungiformis KCTC14777BP and Bacillus megaterium KCTC14778BP of the present invention, cultures of the above-mentioned strains, fermented products of the above-mentioned strains, and fractions of the above-mentioned cultures or fermented products. In addition, the above-mentioned strains, cultures of the above-mentioned strains, fermented products of the above-mentioned strains, and fractions of the above-mentioned cultures or fermented products of the present invention can be added as main components to prepared juices, teas, jellies, fruit juices, etc. for preparation, and can include forms such as pills, powders, granules, agents, tablets, capsules or liquids.

[0107] The above-mentioned health functional food is the same term as the food for special health use (FoSHU), which refers to a food with high medical and therapeutic effects that is processed to effectively exhibit the regulatory functions of living organisms in addition to providing nutrition. Here, "functional" means obtaining useful effects for health care purposes such as regulating nutrients for the structure and functions of the human body or physiological effects. The food of the present invention can be prepared by methods commonly used in the art. During the above preparation, it can be prepared by adding raw materials and components commonly added in the art. In addition, the dosage form of the above food can also be prepared without limitation as long as it is a dosage form recognized as a food. The food composition of the present invention can be prepared in various dosage forms, and different from ordinary drugs, it uses food as the raw material, so it has the advantages of not causing side effects that may occur when taking drugs for a long time, and excellent portability. Therefore, the food of the present invention can be ingested as an adjuvant for enhancing the immune enhancing effect.

[0108] The above-mentioned health food refers to a food that has a positive effect on maintaining or enhancing health compared with ordinary food, and the health supplement food refers to a food for health supplement purposes. Depending on the situation, the terms of health functional food, health food, and health supplement food are used interchangeably.

[0109] Specifically, the above-mentioned health functional food is prepared by adding one or more of the strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP, the culture of the above strains, the ferment of the above strains, and any one or more of the fractions of the above culture or ferment to food materials such as beverages, teas, spices, chewing gums, and biscuits, or prepared into foods such as capsules, powders, and suspensions. And it means that when ingesting them, it will bring specific health effects. Different from ordinary drugs, it uses food as the raw material, so it has the advantage of not causing side effects that may occur when taking drugs for a long time.

[0110] The above composition can additionally contain a physiologically acceptable carrier, and the type of the carrier is not particularly limited and can be arbitrarily used as long as it is a commonly used carrier in the technical field of the present invention.

[0111] In addition, the above composition may contain additional ingredients commonly used in food compositions that can enhance odor, taste, visual appearance, etc. For example, it may contain vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may contain minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc. In addition, it may contain amino acids such as lysine, tryptophan, cysteine, valine, etc.

[0112] In addition, the above composition may contain food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), fungicides (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), color developers (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavors (vanillin, lactones, etc.), swelling agents (alum, potassium bitartrate, etc.), fortifiers, emulsifiers, thickeners (paste), film-forming agents, gum bases, foam inhibitors, solvents, modifiers, etc. The above additives can be selected according to the type of food and used in appropriate amounts.

[0113] Any one or more of the above-mentioned Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP or Bacillus megaterium KCTC14778BP strains, cultures of the above strains, fermentates of the above strains, and fractions of the above cultures or fermentates can be directly added or used together with other foods or food ingredients, and can be appropriately used according to conventional methods. The mixing amount of the active ingredient can be appropriately determined according to its use purpose (prevention, health or therapeutic treatment). Generally, when preparing foods or beverages, the food composition of the present invention can be added in an amount of 50 parts by weight or less, specifically 20 parts by weight or less, relative to the food or beverage. However, when taken long-term for health and hygiene purposes, it may include contents below the above range, and there are no problems in terms of safety, so the active ingredient can also be used in an amount above the above range.

[0114] As an example of the food composition of the present invention, it can be used as a health beverage composition, and in this case, like a conventional beverage, it can contain various flavoring agents or natural carbohydrates, etc. as additional ingredients. The above natural carbohydrates can be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetening agent, natural sweetening agents such as thaumatin and stevia extract can be used; synthetic sweetening agents such as saccharin and aspartame, etc. The proportion of the above natural carbohydrates is usually about 0.01 to 0.04 g per 100 mL of the composition of the present invention, specifically about 0.02 to 0.03 g.

[0115] In addition to the above substances, the health beverage composition can also contain various nutritional agents, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohols or carbonating agents, etc. In addition, it can contain the pulp for preparing natural fruit juice, fruit juice beverage or vegetable beverage. These components can be used alone or in combination. Although the proportion of these additives is not very important, it is generally selected within the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

[0116] Specifically, relative to the total weight of the food composition, the content of any one or more of the strains of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP or Bacillus megaterium KCTC14778BP, the cultures of the above strains, the fermentates of the above strains, and the fractions of the above cultures or fermentates can be 0.00001 to 100% by weight.

[0117] As a specific embodiment of the present invention, a food composition containing Saccharomyces cerevisiae KCTC14779BP for improving wrinkles, improving elasticity, preventing aging or moisturizing the skin can be provided, but not limited thereto.

[0118] As a specific embodiment of the present invention, a food composition containing Saccharomyces cerevisiae KCTC14780BP for calming the skin, regenerating the skin, improving skin inflammation, moisturizing the skin, improving wrinkles, improving elasticity, whitening the skin, antioxidant, anti-aging, calming sensitive skin, improving sensitive skin, relieving erythema, relieving pruritus or strengthening the skin barrier function can be provided, but not limited thereto.

[0119] As a specific embodiment of the present invention, there may be provided a food composition comprising Lactobacillus fructivorans KCTC14776BP for improving wrinkles, for improving elasticity, for preventing aging, for soothing the skin, for improving skin inflammation or for moisturizing the skin, but not limited thereto.

[0120] As a specific embodiment of the present invention, there may be provided a food composition comprising Bacillus paramycoides KCTC14777BP for improving wrinkles, for improving elasticity, for preventing aging or for moisturizing the skin, but not limited thereto.

[0121] As a specific embodiment of the present invention, there may be provided a food composition comprising Bacillus megaterium KCTC14778BP for moisturizing the skin, but not limited thereto.

[0122] Another aspect of the present invention provides a method for preparing a fermented product, comprising a step of fermenting using a strain selected from the group consisting of Saccharomyces cerevisiae deposited under the accession number KCTC14779BP, Saccharomyces cerevisiae deposited under the accession number KCTC14780BP, Lactobacillus fructivorans deposited under the accession number KCTC14776BP, Bacillus paramycoides deposited under the accession number KCTC14777BP, and Bacillus megaterium deposited under the accession number KCTC14778BP.

[0123] The above-mentioned "Saccharomyces cerevisiae", "Lactobacillus fructivorans", "Bacillus paramycoides", "Bacillus megaterium", "strain" and "fermented product" are as described above.

[0124] In the present invention, Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP or Bacillus megaterium KCTC14778BP is placed in a medium and cultured with shaking at 20°C to 40°C for 1 hour to 200 hours, and then the cells are separated by centrifugation, and then the cells are disrupted by ultrasonic treatment, whereby a fermented product can be prepared, but not limited thereto. The medium used in the invention may be MRS medium, R2A medium or LBS medium, but the type of the medium is not limited as long as it can culture or ferment the strain.

[0125] Another aspect of the present invention provides a fraction preparation method, comprising: a step of culturing a Saccharomyces cerevisiae strain deposited under the accession number KCTC14780BP; and a step of separating from the culture or ferment of the strain using water, an alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform or dichloromethane.

[0126] The above-mentioned "Saccharomyces cerevisiae", "strain", "fraction" are as described above.

[0127] Another aspect of the present invention provides a use for improving the skin of a cosmetic composition, which comprises any one or more of the strain of the present invention, the culture of the above-mentioned strain, the ferment of the above-mentioned strain, and the fraction of the above-mentioned culture or ferment.

[0128] Another aspect of the present invention provides a use for improving the skin of a pharmaceutical external composition, which comprises any one or more of the strain of the present invention, the culture of the above-mentioned strain, the ferment of the above-mentioned strain, and the fraction of the above-mentioned culture or ferment.

[0129] Another aspect of the present invention provides a use for improving the skin of a food composition, which comprises any one or more of the strain of the present invention, the culture of the above-mentioned strain, the ferment of the above-mentioned strain, and the fraction of the above-mentioned culture or ferment.

[0130] The above-mentioned "strain", "culture", "ferment", "fraction", "yeast polypeptide", "improve skin", "improve" are as described above.

[0131] Another aspect of the present invention provides a method for improving the skin, which comprises a step of applying or introducing a composition containing any one or more of the strain of the present invention, the culture of the above-mentioned strain, the ferment of the above-mentioned strain, and the fraction of the above-mentioned culture or ferment as an active ingredient to an individual.

[0132] The above-mentioned "strain", "culture", "ferment", "fraction", "yeast polypeptide", "improve skin", "improve" are as described above.

[0133] The term "individual" in the present invention refers to all animals including humans, and the above-mentioned animals can be not only humans, but also mammals such as cows, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. that need to treat similar symptoms, but are not limited thereto.

[0134] In the present invention, the term "apply" refers to all methods of bringing the composition of the present invention into contact with the skin of an individual by any suitable method, and the purpose is to absorb the composition into the skin through this method.

[0135] When the composition of the present invention is applied to the skin of an individual, it can have the effects of improving wrinkles, improving elasticity, preventing aging, moisturizing the skin, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, antioxidation, anti-aging, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, and strengthening the skin barrier function, and may include the step of applying or administering the above composition to an individual in an effective amount to exhibit the above effects.

[0136] In the present invention, the term "administering" refers to the general term for providing a predetermined substance to an individual by any suitable method, and the above administering route can be administered through any general route as long as it can reach the target skin. Specific Examples

[0138] Hereinafter, the present invention will be described in more detail by way of examples. However, these examples are used to illustrate the present invention illustratively, and the scope of the present invention is not limited to these examples.

[0139] Example 1. Isolation of yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP), Lactobacillus (Lactobacillus fructivorans KCTC14776BP), and Bacillus (Bacillus paramycoides KCTC14777BP, Bacillus megaterium KCTC14778BP) strains Isolation

[0140] Novel yeasts, namely Saccharomyces cerevisiae CF2-0w-17 and CF2-0w-22, Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30 strains were obtained from a plant fermentation broth fermented for one year.

[0141] The above Saccharomyces cerevisiae CF2-0w-17 and CF2-0w-22 strains were respectively deposited with the Korean Collection for Type Cultures (KCTC), a depository institution under the Budapest Treaty, on November 16, 2021, and the deposit numbers are KCTC14779BP and KCTC14780BP. It was confirmed that the above strains respectively have the 18s rRNA base sequences of SEQ ID NO: 1 and SEQ ID NO: 2.

[0142] The Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30 strains were respectively deposited with the Korean Collection for Type Cultures (KCTC), a depository institution under the Budapest Treaty, on November 16, 2021, with the deposit numbers KCTC14776BP, KCTC14777BP, and KCTC14778BP. It was confirmed that the above strains respectively have 16s rRNA base sequences of sequence numbers 3, 4, and 5.

[0143] Example 2. Preparation of yeast, Lactobacillus, and Bacillus fermentates and polypeptides extracted from the fermentates

[0144] Example 2-1. Preparation of yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP) fermentate

[0145] The Saccharomyces cerevisiae KCTC14779BP and KCTC14780BP strains were respectively inoculated into a culture medium, and after shaking culture, the respective cells were separated by centrifugation. The cells were suspended in pure water and then ultrasonicated to break the cells, and finally, a Saccharomyces cerevisiae KCTC14779BP or KCTC14780BP ferment was prepared. The specific conditions and compositions are shown in Table 1 below.

[0146] [Table 1]

[0147]

[0148] Example 2-2. Preparation of polypeptides extracted from yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and fractions containing the same Preparation

[0149] The Saccharomyces cerevisiae KCTC14780BP strain was inoculated into a culture medium and subjected to shaking culture. And after separating the cells by centrifugation, a lysate was obtained and concentrated. Thereafter, it was suspended in alcohol at twice the content of the lysate and centrifuged to separate the polypeptide fraction precipitated from the lysate, thereby preparing a fraction containing the yeast of the present invention, the Saccharomyces cerevisiae KCTC14780BP polypeptide.

[0150] Example 2-3. Preparation of Lactobacillus (Lactobacillus fructivorans KCTC14776BP), Bacillus (Bacillus paramycoides KCTC14777BP, Bacillus megaterium KCTC14778P) fermentates

[0151] Lactobacillus fructivorans KCTC14776BP, Bacillus parafungiformis KCTC14777BP, and Bacillus megaterium KCTC14778P strains were respectively inoculated into a medium, and after shaking culture, the cells were separated by centrifugation. The cells were suspended in pure water and then ultrasonically treated to break the cells, and finally, fermented products of Lactobacillus fructivorans KCTC14776BP, Bacillus parafungiformis KCTC14777BP, and Bacillus megaterium KCTC14778P were prepared. The specific conditions and compositions are shown in Table 2 below.

[0152] [Table 2]

[0153]

[0154] Example 3. Confirmation of the effect of yeast, Lactobacillus, and Bacillus fermentates on enhancing collagen synthesis

[0155] Example 3-1. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentate on enhancing collagen synthesis

[0156] Samples were treated at each concentration in human dermal fibroblasts for 48 hours. The collagen synthesis rate was measured using the procollagen type Ι C-peptide (PIP) EIA kit method. For the collagen synthesis effect of the samples, the values were measured by calculating relative to the negative control group (DMEM containing 0% serum).

[0157] To confirm the effect of enhancing collagen synthesis of the fermented product of Saccharomyces cerevisiae KCTC14779BP, the collagen synthesis rates were compared when normal cells, TGF-β-treated normal cells, Saccharomyces cerevisiae KCTC14779BP yeast fermented product-treated cells, and normal yeast (Saccharomyces cerevisiae KCTC 7296) fermented product-treated cells (Table 3).

[0158] [Table 3]

[0159] Sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10 ppb) 27.55 Saccharomyces cerevisiae KCTC14779BP fermentate (1%) 27.22 Normal yeast fermentate (1%) 9.81

[0160] As shown in the results of Table 3 above, it was confirmed that when normal cells were treated with the fermented product of Saccharomyces cerevisiae KCTC14779BP, the collagen synthesis rate increased. At this time, compared with the fermented product of normal yeast prepared under the same conditions, the increase rate of the fermented product of Saccharomyces cerevisiae KCTC14779BP was more excellent.

[0161] Example 3-2. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and fractions containing yeast polypeptides on enhancing collagen synthesis

[0162] The confirmation of the effect of enhancing collagen synthesis was carried out in the same manner as in Example 3-1 above, and the collagen synthesis rates were compared when using normal cells, TGF-β-treated normal cells, fermented product of Saccharomyces cerevisiae KCTC14780BP, and fraction containing yeast polypeptides (Table 4).

[0163] [Table 4]

[0164] Sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10 ng / ml) 23.92 Fraction containing normal yeast fermentate (1%) 9.81 Saccharomyces cerevisiae KCTC14780BP fermentate (1%) 16.38 Fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide (0.01%) 16.99

[0165] As shown in the results of Table 4 above, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides. At this time, compared with the fermented product of normal yeast prepared under the same conditions, the collagen synthesis rates of the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides were more excellent.

[0166] Example 3-3. Confirmation of the effect of Lactobacillus (Lactobacillus fructivorans KCTC14776BP) fermentate on enhancing collagen synthesis Effect

[0167] The confirmation of the effect of enhancing collagen synthesis was carried out in the same manner as in Example 3-1 above, and the collagen synthesis rates were compared when using normal cells, TGF-β-treated normal cells, fermented product of Lactobacillus fructivorans KCTC14776BP, and fermented product of normal Lactobacillus (Lactobacillus plantarum KCTC 3108) (Table 5).

[0168] [Table 5]

[0169] Sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10 ppb) 24.6 Lactobacillus fructivorans KCTC14776BP fermentate (0.1%) 21.77 Normal Lactobacillus fermentate (0.1%) 15.12

[0170] As shown in the results of Table 5 above, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fermented product of Lactobacillus fructivorans KCTC14776BP. At this time, compared with the fermented product of normal Lactobacillus prepared under the same conditions, the increase rate of the fermented product of Lactobacillus fructivorans KCTC14776BP was more excellent.

[0171] Example 3-4. Confirmation of the effect of Bacillus (Bacillus paramycoides KCTC14777BP) fermentate on enhancing collagen synthesis

[0172] The confirmation of the effect of enhancing collagen synthesis was carried out in the same manner as in Example 3-1 above, and the collagen synthesis rates were compared when using normal cells, TGF-β-treated normal cells, fermented product of Bacillus parafungiformis KCTC14777BP, and fermented product of normal Lactobacillus (Bacillus megaterium KCTC 3007) (Table 6).

[0173] [Table 6]

[0174] Sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10 ppb) 20.84 Bacillus paramycoides KCTC14777BP fermentate (0.1%) 33.41 Normal Bacillus fermentate (0.1%) 28.59

[0175] As shown in the results of Table 6 above, it was confirmed that when the fermented product of Bacillus parafungiformis KCTC14777BP was treated with normal cells, the collagen synthesis rate increased. At this time, compared with the fermented product of Bacillus subtilis prepared under the same conditions, the increase rate of the fermented product of Bacillus parafungiformis KCTC14777BP was more excellent.

[0176] Thus, the fermented products of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, the fraction containing yeast polypeptide, Lactobacillus fructivorans KCTC14776BP and / or the fermented product of Bacillus parafungiformis KCTC14777BP of the present invention showed excellent effects in improving skin wrinkles, enhancing elasticity, etc.

[0177] Example 4. Confirmation of the effect of yeast, Lactobacillus, and Bacillus fermentates on enhancing hyaluronic acid synthesis

[0178] Example 4-1. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentate on enhancing hyaluronic acid synthesis

[0179] Samples were treated at each concentration for 72 hours in human keratinocyte HaCaT (Human keratinocyte HaCaT). Using Quantikine ELISA Hyaluronan from R&D systems, hyaluronic acid synthesis was compared with the control group (DMEM treatment containing 0% serum), and the moisturizing ability was quantified (Table 7).

[0180] [Table 7]

[0181]

[0182] As shown in the results of Table 7 above, it was confirmed that when the fermented product of Saccharomyces cerevisiae KCTC14779BP was treated with normal cells, the hyaluronic acid synthesis rate increased. At this time, compared with the fermented product of normal yeast prepared under the same conditions, the increase rate of the fermented product of Saccharomyces cerevisiae KCTC14779BP was more excellent.

[0183] Example 4-2. Confirmation of the effect of enhancing hyaluronic acid synthesis by yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate

[0184] The confirmation of the effect of enhancing hyaluronic acid synthesis was carried out in the same method as in Example 4-1 above (Table 8).

[0185] [Table 8]

[0186]

[0187] As shown in the results of Table 8 above, it was confirmed that when ordinary cells were treated with the fermented product of Saccharomyces cerevisiae KCTC14780BP, the hyaluronic acid synthesis rate increased. At this time, compared with the ordinary yeast fermented product prepared under the same conditions, the hyaluronic acid synthesis rate of the fermented product of Saccharomyces cerevisiae KCTC14780BP was more excellent.

[0188] Example 4-3. Confirmation of the effect of enhancing hyaluronic acid synthesis by Lactobacillus (Lactobacillus fructivorans KCTC14776BP) fermentate Example 4-3. Confirmation of the effect of enhancing hyaluronic acid

[0189] The confirmation of the effect of enhancing hyaluronic acid synthesis was carried out in the same manner as in Example 4-1 above (Table 9).

[0190] [Table 9]

[0191]

[0192] As shown in the results of Table 9 above, it was confirmed that when ordinary cells were treated with the fermented product of Lactobacillus fructivorans KCTC14776BP, the hyaluronic acid synthesis rate increased. At this time, compared with the ordinary lactobacillus fermented product prepared under the same conditions, the increase rate of the fermented product of Lactobacillus fructivorans KCTC14776BP was more excellent.

[0193] synthesis by Bacillus (Bacillus paramycoides KCTC14777BP) fermentate Example 4-4. Confirmation of the effect of enhancing hyaluronic acid synthesis by Bacillus (Bacillus megaterium KCTC14778BP) fermentate

[0194] The confirmation of the effect of enhancing hyaluronic acid synthesis was carried out in the same manner as in Example 4-1 above (Table 10).

[0195] [Table 10]

[0196]

[0197] As shown in the results of Table 10 above, it was confirmed that when ordinary cells were treated with the fermented product of Bacillus parasphaericus KCTC14777BP, the hyaluronic acid synthesis rate increased. At this time, compared with the ordinary bacillus fermented product prepared under the same conditions, the increase rate of the fermented product of Bacillus parasphaericus KCTC14777BP was more excellent.

[0198] Example 5. Confirmation of the effect of enhancing cell activity by yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and the fraction containing yeast polypeptides Sample

[0199] The confirmation of the effect of enhancing hyaluronic acid synthesis was carried out in the same manner as in Example 4-1 above (Table 11).

[0200] [Table 11]

[0201]

[0202] As shown in the results of Table 11 above, it was confirmed that when the fermented product of Bacillus megaterium KCTC14780BP was treated with normal cells, the hyaluronic acid synthesis rate increased. At this time, compared with the fermented product of normal Bacillus prepared under the same conditions, the increase rate of the fermented product of Bacillus megaterium KCTC14778BP was more excellent.

[0203] Thus, the fermented products of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus parafungiformis KCTC14777BP and / or Bacillus megaterium KCTC14778BP of the present invention show excellent effects in improving skin wrinkles, enhancing elasticity, moisturizing, calming the skin, etc.

[0204] Cell viability rate (% of control) Normal cells (negative control group)

[0205] Samples were treated at each concentration in human dermal fibroblasts for 48 hours. The cell viability was measured using the CCK-8 kit (CCK-8 kit) method. For the cell viability efficacy of the samples, the values were measured by calculating relative to the negative control group (DMEM containing 0% serum).

[0206] To confirm the effect of enhancing cell viability of the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide, the cell viability rates were compared when treating normal cells, treating normal cells with FBS, treating with the fermented product of Saccharomyces cerevisiae KCTC14780BP, treating with the fermented product of normal yeast (Saccharomyces cerevisiae KCTC 7296) and treating with the fraction containing yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptide (Table 12).

[0207] [Table 12]

[0208] Normal cells + FBS (positive control group, 5%) Normal yeast fermentate (1%) No effect (-10.89) 0 Saccharomyces cerevisiae KCTC14780BP fermentate (1%) 17.55 Fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptides (0.1%) Example 6. Confirmation of the effect of calming the skin and improving inflammation (inhibiting NO production) by yeast and Lactobacillus fermentates Example 6-1. Confirmation of the effect of calming the skin and improving inflammation (inhibiting NO production) by yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and the fraction containing yeast polypeptides 20.15 Example 6-2. Confirmation of the effect of calming the skin and improving inflammation (inhibiting NO production) by Lactobacillus (Lactobacillus fructivorans KCTC14776BP) fermentate 60.76

[0209] As shown in the results of Table 12 above, it was confirmed that when treating normal cells with the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction fermented product containing yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptide, the cell viability rate increased. At this time, compared with the fermented product of normal yeast prepared under the same conditions, the increase rates of the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide were more excellent.

[0210] As can be seen, the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide of the present invention exhibit excellent effects in terms of cell activity and the like.

[0211] Sample

[0212] NO production inhibitory ability (% of control) Normal cells (negative control group)

[0213] In Raw 264.7 cells, the samples were diluted at each concentration, treated with 1 μg / ml of LPS, and cultured for 24 hours. The inhibitory ability of NO production was evaluated as follows using the NO quantification kit method (Table 13).

[0214] Inhibitory ability of NO production (%) = (1 - (NO production amount when adding the sample / NO production amount when not adding the sample)) x 100

[0215] [Table 13]

[0216]

[0217] As shown in the results of Table 13 above, it was confirmed that when the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide were treated on normal cells, the inhibitory ability of NO production increased. At this time, compared with the normal yeast fermented product prepared under the same conditions, the increase rate of the fermented product of Saccharomyces cerevisiae KCTC14780BP was more excellent.

[0218] Normal cells + L-NMMA (positive control group, 20 μg / mL) Lactobacillus fructivorans KCTC14776BP fermentate (1%)

[0219] The confirmation of the effects of calming the skin and improving inflammation was carried out in the same method as in Example 6-1 above (Table 14).

[0220] [Table 14]

[0221] Normal Lactobacillus fermentate (1%) Example 7. Confirmation of the effect of inhibiting melanin expression by yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and the fraction containing yeast polypeptides Example 8. Confirmation of the effect of scavenging free radicals by yeast (Saccharomyces cerevisiae KCTC14780BP) fermentate and the fraction containing yeast polypeptides 0 Sample 47.9 IC50 (%) 15.1 Positive control group (vitamin C, Vitamin C) 4.9

[0222] As shown in the results of Table 14 above, it was confirmed that when the fermented product of Lactobacillus fructivorans KCTC14776BP was treated on normal cells, the inhibitory ability of NO production increased. At this time, compared with the normal lactobacillus fermented product prepared under the same conditions, the increase rate of the fermented product of Lactobacillus fructivorans KCTC14776BP was more excellent.

[0223] As can be seen, the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide and / or the fermented product of Lactobacillus fructivorans KCTC14776BP of the present invention exhibit excellent effects in terms of calming the skin and improving inflammation and the like.

[0224] Saccharomyces cerevisiae KCTC14780BP fermentateFraction containing Saccharomyces cerevisiae KCTC14780BP polypeptides

[0225] The samples were diluted at each concentration in B16f10 melanocytes, treated for 72 hours and cultured, and then the amount of melanin pigment present in the melanocytes was quantified. The melanogenesis inhibition rate was calculated relative to the total protein amount, and then the value was measured as a percentage calculated based on the DMSO control group (DMEM containing 0% serum, untreated group, negative control group) being 100%.

[0226] To determine the degree of reduction in the amount of melanin pigment in the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, the melanogenesis inhibition rates were compared among the positive control group (Arbutin 200 ppm (Lim YJ et al., 2009, Arch PharmRes.)), the treatment with the fermentation product of Saccharomyces cerevisiae KCTC14780BP, and the treatment with the fraction containing yeast polypeptides (Table 15).

[0227] [Table 15]

[0228]

[0229] As shown in the results of Table 15 above, it was confirmed that the melanogenesis inhibition rate increased when the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides were treated on normal cells.

[0230] Thus, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides of the present invention exhibit excellent effects in whitening the skin.

[0231] Example 9. Confirmation of the effect of calming sensitive skin by the fraction containing yeast polypeptides of yeast (Saccharomyces cerevisiae KCTC14780BP) Example 9-1. Confirmation of the effect of inhibiting the expression of erythema / itching inducer (PGE2) by the fraction containing yeast polypeptides

[0232] After dissolving the sample in DMSO, 0.15 mM DPPH solution was mixed with an equal amount (100 μl) of the sample and reacted at room temperature for 30 minutes. Thereafter, for the color change of DPPH, the absorbance (A540) was measured at 540 nm.

[0233] To evaluate the free radical scavenging ability of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, the IC50 value was obtained by measuring the A540 values in the positive control group (Vitamin C), the treatment with the fermentation product of Saccharomyces cerevisiae KCTC14780BP, and the treatment with the fraction containing yeast polypeptides, thereby comparing the free radical scavenging ability (Table 16).

[0234] [Table 16]

[0235] Example 9-2. Confirmation of the effect of increasing the expression of LOR (Loricrin), the main component strengthening the skin barrier, by the fraction containing yeast polypeptides Example 9-3. Confirmation of the effect of inhibiting inflammatory cytokines by the fraction containing yeast polypeptides Example 9-4. Confirmation of the effect of inhibiting the activity of the skin neurogenic stimulus inducer TRPV1 by the fraction containing yeast polypeptides 0.000606±0.00006 ​ 3.476±0.337 ​ 0.1804±0.0174

[0236] As shown in the results of Table 16 above, when normal cells were treated with the fermented product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, the effect of scavenging free radicals (reactive oxygen species) was confirmed.

[0237] Thus, it can be seen that the fermented product of Saccharomyces cerevisiae KCTC14780BP of the present invention has excellent antioxidant, anti-aging and skin protection effects against external stimuli.

[0238] ​ ​

[0239] ​ ​

[0240] Samples diluted at each concentration and treated with UVB (11 mJ) were cultured in Raw 264.7 cells for 24 hours. The inhibitory ability (%) of PGE2 (Prostaglandin E2) production was evaluated using the PGE2 quantification kit method. Specifically, a standard curve was prepared using 4PL regression, and the effect of UVB-induced PGE2 production was calculated as 100%, and the amount of PGE2 produced when treating the sample was relatively calculated and the value was measured (Table 17).

[0241] [Table 17]

[0242]

[0243] As shown in the results of Table 17 above, when normal cells were treated with the fraction containing the polypeptide of Saccharomyces cerevisiae KCTC14780BP, the effect of inhibiting PGE2 expression was confirmed.

[0244] Thus, it can be seen that the fraction containing yeast polypeptides of the present invention exhibits excellent effects in relieving skin erythema / itching, sedation and improving sensitive skin, etc.

[0245] ​ ​

[0246] After treating HaCaT cells with TNF-α (10 pg / ml) for 3 hours, the samples were diluted at each concentration, mixed with HaCaT cells treated with TNF-α and cultured for 24 hours. The degree of increase in the expression of LOR (Loricrin), the main component of the skin barrier, was quantified using qPCR (Table 18).

[0247] [Table 18]

[0248]

[0249] As shown in the results of Table 18 above, it was confirmed that when normal cells were treated with the fraction containing the polypeptide of Saccharomyces cerevisiae KCTC14780BP, the LOR expression increased.

[0250] Thus, the fraction containing yeast polypeptide of the present invention exhibits excellent effects in strengthening the skin barrier, calming and improving sensitive skin, etc.

[0251] ​

[0252] In HaCaT cells, the samples diluted at each concentration and treated with UVB (11 mJ) were cultured for 24 hours. The expression level of the inflammatory cytokine (TNF-α) expressed in sensitive skin was calculated by qPCR and the values were measured (Table 19).

[0253] [Table 19]

[0254]

[0255] As shown in the results of Table 19 above, it was confirmed that when normal cells were treated with the fraction containing the polypeptide of Saccharomyces cerevisiae KCTC14780BP, the TNF-α expression was inhibited.

[0256] Thus, the fraction containing yeast polypeptide of the present invention exhibits excellent effects in calming and improving sensitive skin, etc.

[0257] ​ ​

[0258] In HEK 293T-TRPV1 cells, the samples were diluted at each concentration and treated. After 10 minutes, the effect of inhibiting TRPV1 (Transient receptor potential vanilloid-1) activity was evaluated using a calcium influx detection assay kit (Table 20).

[0259] [Table 20]

[0260]

[0261] As shown in the results of Table 20 above, it was confirmed that when normal cells were treated with the fraction containing the polypeptide of Saccharomyces cerevisiae KCTC14780BP, the TRPV1 activity was inhibited. At this time, it was confirmed that the effect of inhibiting TRPV1 activity was superior to that of the positive control group treated under the same conditions.

[0262] Thus, it can be seen that the fraction containing yeast polypeptide of the present invention exhibits excellent effects in reducing skin nerve irritation / pain, sedation, and improving sensitive skin, etc.

[0263] Based on the above description, those skilled in the art to which the present invention pertains can understand that the present invention can also be implemented in other specific manners without changing the technical idea or essential features of the present invention. In this regard, it should be understood that the embodiments described above are exemplary in all aspects and not restrictive. The scope of the present invention should include the meaning and scope of the claims described hereinafter and all changes or variations derived from its equivalent concepts, rather than just including the above detailed description.

[0264]

[0265]

[0266]

[0267]

[0268]

Claims

1. A strain, which is a Saccharomyces cerevisiae strain preserved under the accession number KCTC14780BP, wherein the strain is characterized by calming the skin and improving skin inflammation.

2. A cosmetic composition for skin improvement, which comprises a disrupted product of the strain described in claim 1.

3. A pharmaceutical external composition for skin improvement, which comprises any one or more of the strain described in claim 1 and the disrupted product of the strain.

4. Use of a composition in the preparation of a cosmetic composition for skin improvement, the composition comprising a disrupted product of the strain described in claim 1, Among them, wherein the skin improvement is any one or more selected from the group consisting of improving wrinkles, improving elasticity, whitening the skin, antioxidant, anti-aging, calming sensitive skin.

5. Use of the disrupted product of the strain according to claim 1 in the preparation of a cosmetic composition for skin improvement, wherein, The skin improvement is any one or more selected from the group consisting of improving wrinkles, improving elasticity, whitening the skin, antioxidant, anti-aging, calming sensitive skin, or the cosmetic composition is used for enhancing cell activity, inhibiting NO generation, promoting hyaluronic acid synthesis, promoting collagen synthesis, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 (Prostaglandin E2) expression, increasing LOR (Loricrin) expression, inhibiting TNF-a expression or inhibiting TRPV1 activity.

6. Use of a pharmaceutical external composition in the preparation of a pharmaceutical external composition for skin improvement, the pharmaceutical external composition comprising any one or more of the strain described in claim 1 and the disrupted product of the strain, Among them, wherein the skin improvement is any one or more selected from the group consisting of improving wrinkles, improving elasticity, whitening the skin, antioxidant, anti-aging, calming sensitive skin.

7. Use of any one or more of the strain according to claim 1 and the disrupted product of the strain in the preparation of a pharmaceutical external composition for skin improvement, wherein, The skin improvement is any one or more selected from the group consisting of improving wrinkles, improving elasticity, whitening the skin, antioxidant, anti-aging, calming sensitive skin, or the pharmaceutical external composition is used for enhancing cell activity, inhibiting NO generation, promoting hyaluronic acid synthesis, promoting collagen synthesis, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 (Prostaglandin E2) expression, increasing LOR (Loricrin) expression, inhibiting TNF-a expression or inhibiting TRPV1 activity.

8. A food composition, which comprises any one or more of the strain described in claim 1 and the disrupted product of the strain.

9. A method for preparing a fermented product, comprising the step of fermenting a Saccharomyces cerevisiae strain preserved under the accession number KCTC14780BP.

10. A method for preparing a fraction containing polypeptides, comprising: the step of culturing a Saccharomyces cerevisiae strain preserved under the accession number KCTC14780BP; and the step of separating from the fermented product of the strain using water, an alcohol having 1 to 4 carbon atoms, hexane, ethyl acetate, chloroform or dichloromethane.

Images